|Bid||47.40 x 1300|
|Ask||47.41 x 3000|
|Day's range||46.47 - 47.41|
|52-week range||44.30 - 63.69|
|Beta (3Y monthly)||0.85|
|PE ratio (TTM)||15.07|
|Earnings date||24 Jul 2019 - 29 Jul 2019|
|Forward dividend & yield||1.64 (3.53%)|
|1y target est||57.30|
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst.
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
PRINCETON, N.J.--(BUSINESSWIRE)-- New data on Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with advanced hepatocellular carcinoma and in melanoma patients with symptomatic brain metastases New ...
PRESS RELEASE : 16 May 2019, 07:00 CEST Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference Mechelen, Belgium, 16 May 2019 - Biocartis Group NV (the `Company` or `Biocartis`), ...
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
Two-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis. Survivorship Today: What It’s Like to Live with Cancer explores the stories of people who have experienced lasting physical, emotional and social effects from cancer to build greater understanding of, and draw attention to, survivorship-related issues. Today, more people who have been diagnosed with cancer are able to live with the disease than ever before.
Bristol-Myers Squibb Company will take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 2:30 p.m.
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bristol-Myers Squibb Company today announced the Phase 3 CheckMate -498 trial evaluating Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase -unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.
Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.